Scientific Poster , Iain Shaw , Human ADME , Clinical Pharmacology

ISSX 2022: A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes

14 December 2022
Overview

With a draft FDA guidance (Clinical Pharmacology Considerations for Human Radiolabelled mass Balance Studies, FDA, May 2022 ) under review there is currently considerable interest in the design and conduct of human mass balance studies. 

In the last 10 years Quotient Sciences have performed close to 200 radiolabelled studies. In that period, study designs have (where required) been adapted to address the challenges presented by new drug candidates, to benefit from new technologies and with a better understanding of how to interpret the data that can be generated from the analysis of collected samples. This poster reviews some of the outcomes from those programs. 

Presented as part of the 2022 The International Society for the Study of Xenobiotics (ISSX) conference in Seattle, WA, USA.

Download
Date
14 December 2022

Your challenges. Our solutions.

Learn more about our expertise in human ADME studies.

Quotient Sciences Logo
Human ADME, Regulatory, Dr. Adam Robinson-Miller

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read More
Get in touch
Humanity can't afford to wait, so neither can we.